TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00198978
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01881048
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03457233
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
Study: NCT00124566
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive oral capecitabine at a dose of 1000 mg/m\^2 twice daily for 15 days every 28 days.
Study: NCT04444752
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous(SC) injection
Study: NCT00206622
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01952470
Drug: Isotonic Saline.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Study: NCT04993222
Drug: AmBisome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04169906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo once daily for 7 consective days
Study: NCT04169906
Drug: TS-142, 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 10 mg of TS-142 once daily for 7 consective days
Study: NCT04169906
Drug: TS-142, 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 mg of TS-142 once daily for 7 consective days
Study: NCT04169906
Drug: TS-142, 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 30 mg of TS-142 once daily for 7 consective days
Study: NCT03456609
Drug: shenqifuzheng injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
Study: NCT00789828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
Study: NCT02828228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once a day for 26 weeks
Study: NCT01067859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of placebo during 48 hours
Study: NCT02628769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02991508
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04070755
Drug: FMX-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01611948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg/d placebo pill for 8 weeks
Study: NCT02148783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03092089
Drug: Definity, (Lipid Microspheres) Intravenous Suspension
Normalized name: Definity, (lipid microspheres) intravenous suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
Study: NCT00085735
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02615873
Drug: Accordion Pill™ Carbidopa/Levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
Study: NCT02657486
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01824875
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02584244
Drug: LUM015
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00860574
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02014649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01192464
Drug: autologous CAR.CD30 EBV specific-CTLs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
Study: NCT04322227
Drug: Placebo (treatment C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, BID capsules, orally
Study: NCT02919306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
Study: NCT00707850
Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]
Study: NCT01187719
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
Study: NCT02342249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo of Oseltamivir
Study: NCT03343392
Drug: acetam/ketoro tromet group
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
Study: NCT03343392
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
Study: NCT00161421
Drug: Oral Testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
Study: NCT04588532
Drug: BAM8-22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine Adrenal Medulla will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Study: NCT04588532
Drug: Cowhage (Mucuna Pruriens)
Normalized name: cowhage (Mucuna pruriens)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cowhage spicules will be applied to 2 previously determined area on the volar forearm (one alone and one in combination with doxepin)
Study: NCT03778359
Drug: Progestins
Normalized name: PROGESTINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
Study: NCT04551352
Drug: RO7293583
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7293583 will be administered at a dose and per schedule as specified for the respective cohort.
Study: NCT02571127
Drug: Hidra1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient.
Study: NCT03823404
Drug: COR388 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID (twice daily)
Study: NCT03823404
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT02334787
Drug: 0.3% OPA-15406 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Study: NCT02334787
Drug: 1% OPA-15406 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
Study: NCT02334787
Drug: 3% OPA-15406 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
Study: NCT02334787
Drug: Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
Study: NCT04085367
Drug: MAL 16.8% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day light photodynamic therapy with MAL 16.8% cream
Study: NCT04085367
Drug: MAL Vehicle Cream
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day light photodynamic therapy with MAL vehicle cream
Study: NCT03729362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
Study: NCT00847171
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
Study: NCT01129102
Drug: NPC-01
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone 1mg, Ethinyl estradiol 0.02mg
Study: NCT01129102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for NPC-01
Study: NCT06190340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration orally.
Study: NCT02103725
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01273376
Drug: RX-10100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tablet, taken twice daily for 8 weeks
Study: NCT00124475
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05436769
Drug: Klaribact 500 mg Clarithromycin Tablet
Normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study: NCT05436769
Drug: Klaricid 500 mg Clarithromycin Tablet
Normalized name: clarithromycin 500 MG
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose consisting of one Tablet of either test drug (Klaribact 500 mg) or reference drug (Klaricid 500mg) administered to each of the subjects in fasting condition with 240 mL water in both Periods alternatively.
Study: NCT04573751
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy as follows: adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study: NCT04573751
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard therapy plus epinephrine as follows: epinephrine, adenosine, nitroglycerine, thrombus aspiration/extraction, and platelet IIb/IIIa receptor inhibitors.
Study: NCT00943709
Drug: therapeutic insulin
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutaneously
Study: NCT01291199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. 6 weeks bid
Study: NCT00068211
Drug: ILX651
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00503932
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m\^2 by mouth (PO) twice daily on days receive radiation.
Study: NCT03748641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo once daily.
Study: NCT00862303
Drug: IL-2/IFN-α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive treatment of IL-2 or IFN-α.
Study: NCT01878643
Drug: vancomycin or gentamicin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
Study: NCT01878643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline administered to patient via nebulization
Study: NCT00616434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IM injection, self-administered per protocol.
Study: NCT04350346
Drug: Motilitone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Ingredients and content: corydalis tuber, pharbitis seed 50% EtOH extracts 30mg~2. Dosage method: Usually, adults take 1 tablet 3 times a day orally before meals.~3. Pharmacological action:~   * It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.~     * Stimulates stomach smooth muscle contraction by suppressing the effect of dopamine on acetylcholine secretion by inhibiting D2 receptor ③ It shows a pharmacological action that stimulates gastrointestinal movement by acting in combination with 5-HT1A / B receptor.
Study: NCT03442764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04021498
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
Study: NCT03387644
Drug: Control placebo (C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets one hour before the procedure as premedication.
Study: NCT04606433
Drug: GNC-038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion.
Study: NCT02612051
Drug: GSK3008348 Nebuliser solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
Study: NCT00738192
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Study: NCT00738192
Drug: Sufentanil citrate
Normalized name: Sufentanil Citrate
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
Study: NCT02813135
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02813135
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01917578
Drug: TAC,TC,TA,CAF,CEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~2. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~3. TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~4. CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~5. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
Study: NCT01017367
Drug: MDX-1100
Normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
Study: NCT01017367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01917578
Drug: AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~2. TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~3. AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~4. TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~5. TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~6. CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)
Study: NCT02477007
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Study: NCT02477007
Drug: paracetamol + ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
Study: NCT02477007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
Study: NCT01480271
Drug: 20ng GSK2445053
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ng GSK2445053 administered intranasally
Study: NCT01480271
Drug: 100ng GSK2445053
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ng GSK2445053 administered intranasally
Study: NCT01480271
Drug: 1000ng GSK2445053
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000ng GSK2445053 administered intranasally
Study: NCT01480271
Drug: 2000ng GSK2445053
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000ng GSK2445053 administered intranasally
Study: NCT01480271
Drug: 4000ng GSK2445053
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000ng GSK2445053 administered intranasally
Study: NCT01480271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intranasally
Study: NCT02184507
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
Study: NCT00362856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT04140526
Drug: ONC-392
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.
Study: NCT03916510
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
Study: NCT00741325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02224599
Drug: Cyclophosphamide Pill
Normalized name: cyclophosphamide Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
Study: NCT03402178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
Study: NCT02067442
Drug: oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 milligrams given orally before surgery
Study: NCT02067442
Drug: intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 milligrams of intravenous acetaminophen given before surgery
Study: NCT02616614
Drug: Clindamycin/benzoyl peroxide gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic Clindamycin/benzoyl peroxide gel for treating acne